Cancer and the Immune System Flashcards

1
Q

what are tumors/neoplasms?

A

cells that have lost control of the cell cycle

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

what are the two types of tumors/neoplasms?

A
  • benign: unable to invade healthy surrounding tissue, incapable of indefinite growth
  • malignant: becomes progressively more invasive and may metastasize
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

what are the three types of hematological system cancers?

A
  • leukemia
  • lymphoma
  • myeloma
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

what causes leukemia?

A

cells of myogenous or lymphocytic origin in early stage of development in bone marrow

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

what causes lymphoma?

A

blood cells in their later stage of development outside the bone marrow spread through lymphatics to lymph nodes

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

what causes myeloma?

A

full differentiated plasma cells that mutated, produce antibodies, migrate back to bone marrow and form multiple lesions

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

how can a malignant transformation of cells be induced?

A
  • chemical substances
  • physical agents
  • ionizing radiation
  • viruses/infectious agents
  • genetic predispositions
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

what are the two ways malignant cell transformations can occur?

A

through DNA alterations or cancer-associated genes

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

what are the three cancer-associated genes and how do they cause cancer?

A
  • proto-oncogenes: genes that induce cellular proliferation become unregulated and cause uncontrolled cell growth
  • tumor-supressor genes: inhibitors of cell proliferation (pro-apoptotic) mutates and allows cancer cells to survive when they fail
  • apoptosis gene problem: abnormal cell survival
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

how can inflammatory responses promote cancer?

A

because chronic inflammation
- increases cellular stress signals
- lead to genotoxic stress
- increase mutation rates
- growth factors/ cytokines released by cells often induce proliferation
- inflammation is proangiogenic

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

what are the two types of tumor antigens?

A
  • tumor-specific antigens
  • tumor-associated antigens
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

what are tumor specific antigens?

A

unique to cancer cells, not found on normal cells, that arise due to genetic mutations or viral infections that create new, abnormal proteins where the immune system can recognize them as non-self and attack them.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

what are tumor associated antigens?

A

Not unique to cancer cells—these are normal proteins but are expressed abnormally in tumors that are normally present during fetal development but reappear in cancer or proteins usually present at low levels but over expressed in tumors

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

what are some examples of tumor specific antigens?

A

Viral
- HPV: L1, E6, E7 - causes cervical carcinoma
- HBV: HBsAg - causes hepatocellular carcinoma

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

what are some examples of tumor-associated antigens?

A

Over expression
- HER-2/neu - causes breast, melanoma, ovarian, gastric and pancreatic
- PSA - prostate
- PAP - prostate
Differentiation Stage
- CEA - colon
- AFP - Hepatocellular carcinoma

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

why is the immune response (immunoediting) to cancer considered a double edged sword?

A

the immune system both protects against tumor growth and shapes the evolution of cancer cells. It consists of three phases

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

what are the three phases and the outcome of immunoediting?

A
  • elimination: attacking the cells that can be targeted
  • equilibrium: state of balance between destruction/survival of “best” cells
  • escape: most aggressive/least immunogenic cells thrive and spread
  • outcome: anti-tumor responses select for toughest cells
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

what are the innate cells that mediate tumor elimination and how?

A
  • NK cells
  • M1 macrophages: activated macrophages secrete TNF (strong anti-tumor activity) and bind to antibody coated tumor cells
  • eosinophils: role not completely established yet
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

what are the adaptive cells that mediate tumor elimination and how?

A
  • T cells
  • Tumor-infiltrating lymphocytes: combination of T cells, NKT cells and NK cells
  • B cells: generate anti-tumor antibodies against tumor specific antigens
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

how do NK cells regulate innate/adaptive cancer immunity?

A

cytokine secretion

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

explain the process of activation for a NK cell?

A
  • cell is missing MHC 1 molecule
  • cell is turned on through immunoreceptor tyrosine based activation motifs (ITAMS)
  • phosphorylation of protein tyrosine kinases
  • production of INF gamma and increase in IL-2 receptors
  • lytic machinery
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

explain the process of no activation for a NK cell?

A
  • inhibitory receptors bind to MHC class 1 molecules
  • immunoreceptor tyrosine based inhibitory motifs are activated
  • recruitment of phosphatases
  • removal of phosphate groups (no protein tyrosine kinase activation)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

how do NK cells recognize a target?

A
  1. inhibitory NK receptors (KIR3DL1) that binds to ligand MHC
  2. activating NK receptors (NKG2D): that bind to ligand, NKG2DL = MICA
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

what is MICA?

A
  • MICA stands for MHC Class I-related chain expressed in various tumors
  • It is expressed on melanomaand is an NKG2D ligand for the activation of NK cells
25
Q

what are the 3 other activation mechanisms for NK cells?

A
  • ADCC: NK cells express FcγRIII (CD16) , which is a receptor for the Fc region of IgG antibodies that causes cytolysis
  • DAMPS: NK cells express NKG2D, an activating receptor that recognizes DAMPs on stressed or abnormal cells
  • DEATH RECEPTORS: Fas cell death
    receptor (CD95), and TNF-relatedapoptosis-
    inducing ligand receptor (TRAILR) induce the
    process of cell death when ligands that are released by NK cells bind
26
Q

what is the mechanism of leathal hit used by CTL and NK cells?

A
  1. recognition
  2. adhesion and formation of conjugates
  3. transient calcium influx
  4. rearrangement of the cytoskeleton
  5. polarization of granules, golgi and microtubule organization center
  6. exocytosis of granules
  7. apoptosis (perforin mediated for CTL or FasL/Fas pathway for NK cells)
27
Q

how do perforins and granzymes cooperatively cause apoptosis?

A
  • perforin molecules polymerize and insert into the target cell membrane, forming pores or channels.
  • pores allow the entry of granzymes and other molecules into the target cell
28
Q

what is a granzyme and what do they do?

A

a family of structurally related serine proteases stored in cytotoxic granules
- Granzyme A induces loss of mitochondrial inner membrane potential, the release of
reactive oxygen species (ROS), and generates nicks in DNA strands.
- Granzyme B activates caspases.

29
Q

what happens once granzyme B activates the caspases?

A
  • leads cells to die of apoptosis
  • FasL/Fas pathway can also mediate apoptosis.
30
Q

what do NKT cells recognize?

A
  • lipid-containing molecules, α-galactosylceramide(α-GalCer), on cancer cells
31
Q

what are the two subsets of NKT cells that cross-regulate eachother?

A
  • Type I NKT cells - promote anti-tumor immunity
  • Type II NKT cells - suppress tumor immunity
32
Q

how do type 1 NKT cells promote anti-tumor immunity?

A
  • Produce IFNγ to induce other effector cells downstream, especially NK cells and CD8+T cells
  • Activate DCs to make IL-12 and also be more effective in antigen-presentation
  • Have lytic granules, perforin, and granzymes lyse a variety of tumor cells
33
Q

what are the cytokines that fight cancer and how do they?

A
  • IFN- γ - All interferon types enhance tumor cell removal activities of immune cells
  • IL-12 - Encourages DCs to activate strong TH1 and CTL responses
  • TNF-α may promote or inhibit anticancer effects; its role in cancer immunity is complex
34
Q

what is involved with the evasion of immune elimination for immunosuppressive tumor microenvironments?

A

induction of suppressive cells

35
Q

what are the suppressive cells that are located in the tumor areas?

A
  • T reg cells
  • Type II NKT cells that suppress tumor immunity
  • suppressive macrophages
36
Q

how do Type II NKT cells suppress tumor immunity?

A
  • suppress immunosurveillance
  • promote only regulatory cells including regulatory T cells and suppressive macrophages
37
Q

what are examples of suppressive macrophages?

A
  • tumor associated macrophages (TAM)
  • alternatively activated macrophages (M2)
  • myeloid derived suppressor cells (MDSCs)
38
Q

what is one of the most immunosuppressive cytokines known and what cell secretes it?

A
  • TGF-β
  • myeloid derived suppressor cells (MDSCs)
39
Q

what are examples of soluble factors that suppress immunity?

A
  • TGF-β
  • IL-10
  • Indoleamine-2,3-dioxygenase (IDO)
40
Q

how does IDO suppress immunity?

A

– allows tumor cells to escape - deplete tryptophan and generate kynurenine, promotes the generation of cells and is toxic to T cells and NK cells

41
Q

how do tumors evade immunity by co-inhibitory signals?

A
  • tumors may express inhibitory second signal molecules (PD-L1) that turn off / exhaust the T cells
42
Q

why are antitumor antibodies NOT always GOOD?

A
  • Antibodies may bind and block tumor antigens that CTLs would otherwise target
  • Antibodies may form complexes with shed tumor antigens
  • The complexes can impair the anti-tumor activities of NK cells and macrophages, which carry Fc receptors for ADCC and opsonization
43
Q

what are the four loosely organized drug therapies for cancer?

A
  • chemotherapies: aimed to block DNA synthesis and cell division
  • hormonal therapies: interfere with tumor cell growth
  • targeted therapies: small molecule inhibitors of cancer
  • immunotherapies: induce or enhance the anti-tumor immune response
44
Q

what are the 5 types of cancer immunotherapies?

A
  • monoclonal antibodies
  • adoptively transferred, antigen loaded dendritic cells
  • adoptively transferred T cells
  • engineered T cells
  • immune checkpoint therapy
45
Q

explain how toxin-conjugated monoclonal antibodies work?

A

a toxic molecule is chemically attached (or conjugated) to a monoclonal antibody that is designed to specifically target a tumor antigen which allows the toxic molecule to be delivered directly to the tumor cells

46
Q

what is an example of a toxic molecule that is conjugated with a monoclonal antibody in cancer immunotherapy?

A

ricin

47
Q

what are some successes of toxic-conjugated monoclonal antibodies?

A
  • mAb against HER2 receptor in breast cancer
  • mAb against CD20 B-cell marker (Rituximab)
    for non-Hodgkin’s lymphoma
  • anti-idiotype mAb for terminal B-cell lymphoma
48
Q

what is the goal of cancer vaccines?

A

enhance the anti-tumor immune response

49
Q

how are cancer vaccines created?

A
  • cultures patient DCs with cancer antigens and enhances antigen presentation with myeloid cell stimulation using GM-CSF
  • the “Primed” DCs are reinfused to activate T cells
  • the provoked CD4 T helper and CD8 CTL recognize and kill tumor cells
50
Q

what is tumor-infiltrating lymphocyte therapy?

A

cells called Lymphokine Activated Killers (LAK) are derived from natural killer (NK) cells or T-cells and are activated and expanded using IL-2 cytokine in the laboratory (ex vivo) to enhance their ability to target and destroy cancer cells

51
Q

what is CAR-T cell therapy?

A

CAR stands for Chimeric Antigen Receptor, a combination of parts from BCR and TCR that allows T-cells to recognize and attack cancer cells without needing antigen presentation

52
Q

when is CAR-T cell therapy used and how does it work?

A
  • used for patients with few treatment options, primarily for leukemia, lymphoma, and myeloma.
  • The B part, VH and VL, recognizes tumor
  • The T part, CD3-zeta signaling domains receptor activates the T-cell to attack the tumor
53
Q

what is the process for making CAR-T cells?

A
  • Harvest the patient’s T-cells
  • Use a lentivirus vector to insert the CAR gene into T-cells
  • Modify T-cells are then reinfused into the patient to target and kill cancer cells
54
Q

what is the benefit of CAR-T cell therapy?

A

No need for MHC matching, allows sustained T-cell activation and tumor destruction.

55
Q

what are the 3 generations of CAR-T cells?

A

First generation: Simple design with only activation signals.
Second generation: Adds dual signaling (e.g., CD28) for better T-cell activation, growth, and survival.
Third generation: Includes multiple signaling (e.g., OX40, CD137) to boost T-cell persistence and anti-tumor activity.

56
Q

what are the side effects of CAR-T cell therapy?

A
  • Cytokine release syndrome: An overactive immune response can lead to excessive inflammation
  • Neurotoxicity: caused by inflammation
57
Q

what is the purpose of Immune checkpoint therapy and what does it target?

A
  • Decrease immune suppressive mechanisms and enhance anti-tumor responses in the tumor microenvironment
  • Targets regulatory pathways (checkpoints) in T cells
58
Q

what are two checkpoint antibodies used for immune checkpoint therapy?

A
  • Anti-CTLA-4
  • Anti-PD-1s
59
Q

what is a side effect of checkpoint therapies?

A

The patient receiving the therapy frequently suffers from immune-related adverse events such as dermatologic, gastrointestinal, endocrine, or hepaticautoimmunereactions.